Cargando…

Rifaximin Therapy of Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain and altered bowel habits in the absence of specific organic pathology. Although the underlying pathogenesis of IBS is not well-understood, small intestinal bacterial overgrowth (SIBO) or other abnorm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koo, Hoonmo L., Sabounchi, Saman, Huang, David B., DuPont, Herbert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987760/ https://www.ncbi.nlm.nih.gov/pubmed/24833932 http://dx.doi.org/10.4137/CGast.S7382

Ejemplares similares

The role of rifaximin in the treatment and chemoprophylaxis of travelers’ diarrhea
por: Koo, Hoonmo L, et al.
Publicado: (2009)

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review
por: Chey, William D., et al.
Publicado: (2020)

Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin
por: DuPont, Herbert L., et al.
Publicado: (2016)

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
por: Iorio, Natalya, et al.
Publicado: (2015)

Chemotactic Chemokines Are Important in the Pathogenesis of Irritable Bowel Syndrome
por: Darkoh, Charles, et al.
Publicado: (2014)

Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Lembo, Anthony, et al.
Publicado: (2020)

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome
por: Jolley, John
Publicado: (2011)

Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
por: Boltin, Doron, et al.
Publicado: (2014)

Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile
por: Gupta, Kamesh, et al.
Publicado: (2017)

Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
por: Li, Jun, et al.
Publicado: (2016)

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
por: Chang, Christopher
Publicado: (2018)

Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome
por: Acosta, Andrés, et al.
Publicado: (2016)

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
por: Pimentel, M., et al.
Publicado: (2017)

Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Rezaie, Ali, et al.
Publicado: (2019)

Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis
por: Schrodt, Caroline, et al.
Publicado: (2013)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
por: Vicari, Enzo, et al.
Publicado: (2014)

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome
por: Zeber-Lubecka, Natalia, et al.
Publicado: (2016)

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2020)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
por: Bae, Suhyun, et al.
Publicado: (2015)

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach
por: Soldi, Sara, et al.
Publicado: (2015)

Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?
por: Tocia, Cristina, et al.
Publicado: (2021)

Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Khan, Zarghuna, et al.
Publicado: (2023)

Irritable bowel syndrome: Is it “irritable brain” or “irritable bowel”?
por: Padhy, Susanta Kumar, et al.
Publicado: (2015)

Therapy of the postinfectious irritable bowel syndrome: an update
por: IACOB, TEODORA, et al.
Publicado: (2017)

Mechanism-Oriented Therapy of Irritable Bowel Syndrome
por: Malagelada, Juan R., et al.
Publicado: (2016)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)

Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity
por: Liu, Zuojing, et al.
Publicado: (2022)

Irritable Bowel Syndrome: Yoga as Remedial Therapy
por: Kavuri, Vijaya, et al.
Publicado: (2015)

Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome
por: Vicari, Enzo, et al.
Publicado: (2017)

Targeted therapies for diarrhea-predominant irritable bowel syndrome
por: Olden, Kevin W
Publicado: (2012)

The epidemiology of irritable bowel syndrome
por: Canavan, Caroline, et al.
Publicado: (2014)

Diet in irritable bowel syndrome
por: El-Salhy, Magdy, et al.
Publicado: (2015)

Biomarkers of Irritable Bowel Syndrome
por: Kim, Jae Hak, et al.
Publicado: (2017)

Pharmacotherapy for Irritable Bowel Syndrome
por: Camilleri, Michael, et al.
Publicado: (2017)

Postinfection Irritable Bowel Syndrome
por: Ghoshal, Uday C
Publicado: (2022)

Irritable Bowel Syndrome and Resilience
por: Fadgyas Stanculete, Mihaela, et al.
Publicado: (2023)

Genetics of irritable bowel syndrome
por: Henström, Maria, et al.
Publicado: (2016)

Irritable bowel syndrome and diet
por: Portincasa, Piero, et al.
Publicado: (2017)

The neurobiology of irritable bowel syndrome
por: Mayer, Emeran A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3fkroq56a01m2dmi7ll745nch9